The Final CRISPRMED24 Program is Now Available

Download the Final CRISPRMED24 Program here.

Registration Deadlines

• In-person Event (April 23-25): Deadline - April 8th.?
• Virtual Event (April 22nd): Deadline - April 21st.?

Please register here, if you would like to secure your pass for the in-person event and/or the virtual event.

In-person Event (April 23-25th)

More than 400 scientists will attend the in-person event in Copenhagen, Denmark. Check out below the confirmed companies and organisations you will meet this year.

Virtual Event (April 22nd)

If you can not attend the in-person event in Copenhagen 23-25 April, remember that we will host a virtual event on the 22nd April, to which anyone can register and be part of the Virtual poster session and view the selected talks (see below).

Selected Speakers:

• Brian Cosgrove, Principal Scientist, Tune Therapeutics and the research lead for the Hepatitis B program. Talk:?Epigenome Editing for the Effective Treatment of HBV.

• Alvin Luk, Co-Founder, CEO, Head of Medical at HuidaGene Therapeutics. Talk:?Advances and Challenges of Next-Generation CRISPR Gene-Editing Technology for Drug Development.?

• Veronika Jekerle, PhD, Head of Pharmaceutical Quality, Human Medicines, European Medicines Agency (EMA). Talk:?EMA’s Experience & Support to the Development of Medicinal Products using Genome Editing.

?

Check out the preliminary?virtual?program here.

When you register for the virtual event, you will also get access on-demand to all the presentations from the in-person event after the conference and a free 12 months CMN+ subscription.

Panel Discussion: Standards and Regulations, April 24th, 9:30 - 10:15 AM CEST

Meet the Panelists:

• Samantha Maragh, Dr., Leader, Genome Editing Program, National Institute of Standards & Technology (NIST), USA.
• Attila Sebe, MD, PhD., Clinical Assessor Advanced Therapy Medicinal Products (ATMPs), Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Division of Haematology, Cell and Gene Therapy, Germany.
• Lotte Dahl Nissen, MSc, Ph.D., Non-clinical Assessor, Quality Assessment & Clinical Trials, Danish Medicines Agency (DKMA), Denmark.
• Veronika Jekerle, PhD, Head of Pharmaceutical Quality, Human Medicines, European Medicines Agency (EMA).

Sponsors, Exhibitors and Supporters

If you can not attend this year, reserve already the dates for the 2nd CRISPR Medicine Conference, CRISPRMED25 - Stay updated here